Critical Diagnostics rolled out its Aspect-LF cardiac disease test for the biomarker ST2, a point-of-care version of the company's lab-based Presage ST2 assay. The test, which Critical aims to make available in Europe and some Asia-Pacific countries later this year, delivers results in about 20 minutes from a single finger prick, assessing a patient's risk of heart failure without sending blood to the lab. The launch makes Aspect-LF the only point-of-care ST2 biomarker test available commercially. Release